# A-Brave (NCT02926196)

> Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02926196
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Istituto Oncologico Veneto IRCCS
- Conditions: Triple Negative Breast Neoplasms
- Interventions: MSB0010718C
- Enrollment: 474
- Primary outcome: Disease free survival
- Primary outcome: Disease free survival in PD-L1-positive patients

## Commentary we found

- X threads: 40
- YouTube: 17
- Podcasts: 10

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=a-brave-nct02926196

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02926196", "email": "<work email>"}; the inbox owner confirms by the emailed link.